Waypoint Capital Advisors LLC Purchases Shares of 627,089 Apogee Therapeutics, Inc. (NASDAQ:APGE)

Waypoint Capital Advisors LLC bought a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 627,089 shares of the company's stock, valued at approximately $36,835,000. Apogee Therapeutics makes up about 7.8% of Waypoint Capital Advisors LLC's holdings, making the stock its 2nd largest position. Waypoint Capital Advisors LLC owned about 1.07% of Apogee Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. EntryPoint Capital LLC increased its position in Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after acquiring an additional 617 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Apogee Therapeutics during the 2nd quarter valued at about $143,000. Kennedy Capital Management LLC bought a new position in shares of Apogee Therapeutics in the 1st quarter worth approximately $212,000. Arizona State Retirement System boosted its holdings in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock worth $236,000 after buying an additional 258 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Apogee Therapeutics by 26.3% in the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock worth $253,000 after buying an additional 1,340 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 7,335 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $40.67, for a total transaction of $298,314.45. Following the completion of the transaction, the insider now directly owns 287,458 shares in the company, valued at approximately $11,690,916.86. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Michael Thomas Henderson sold 40,000 shares of the business's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00. Following the transaction, the chief executive officer now directly owns 1,434,487 shares in the company, valued at $58,268,861.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Carl Dambkowski sold 7,335 shares of the company's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $40.67, for a total value of $298,314.45. Following the completion of the transaction, the insider now directly owns 287,458 shares of the company's stock, valued at approximately $11,690,916.86. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,665 shares of company stock valued at $7,058,635 over the last quarter. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Trading Down 4.8 %

APGE stock traded down $2.70 during midday trading on Friday, reaching $53.53. 481,519 shares of the company's stock traded hands, compared to its average volume of 507,218. Apogee Therapeutics, Inc. has a 52-week low of $14.19 and a 52-week high of $72.29. The stock has a market cap of $3.13 billion, a P/E ratio of -10.20 and a beta of 2.75. The stock's 50-day moving average is $51.94 and its 200 day moving average is $48.61.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting analysts' consensus estimates of ($0.60). As a group, research analysts expect that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.